NDAINTRAVENOUSSOLUTION
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
4/8 — Partial
TPOXX (tecovirimat monohydrate) by Siga is cytochrome p450 3a inducers [moa]. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TPOXX (tecovirimat monohydrate) is an IV solution that inhibits the orthopoxvirus VP37 envelope wrapping protein, blocking viral maturation and spread. It is approved for the treatment of orthopoxvirus infections, including mpox (monkeypox). The drug works as a cytochrome P450 3A inducer targeting a critical viral replication mechanism.
Peak4.9 years to LOE
Product is in peak lifecycle with no current competitive pressure, suggesting stable market position and established commercial infrastructure.
Mechanism of Action
Cytochrome P450 3A Inducers
Pharmacologic Class:
Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Started Jun 2022
44 enrolled
Smallpox
Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Started Apr 2022
100 enrolled
Smallpox
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Started Mar 2022
467 enrolled
Smallpox
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
Started Jan 2020
0Smallpox
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
Started Jul 2019
34 enrolled
Smallpox
Worked on TPOXX at Siga? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.